A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Stopped Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.
Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
Interventions
- BIOLOGICAL: ONCT-808
- DRUG: Bridging Therapy
Sponsor
Oncternal Therapeutics, Inc